報價延遲最少15分鐘:2025/09/03 18:55 EDT
盤後時段
|
||||
|
6.39 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.4
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-37.38/-13.90
|
|
企業價值
6.81M
|
| 資產負債 |
|
每股賬面淨值
-1.51
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/03 18:55 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
